Birdwatch Note
2023-05-16 15:34:28 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
The source in the follow-up tweet explains that these grants were to the National Cancer Institute, not personally to Dr. Bertagnolli. And the bulk of the huge dollar amount was an for a 6,000-patient cancer drug trial. https://www.dailysignal.com/2022/08/22/biden-picks-major-recipient-of-pfizer-research-dollars-to-oversee-cancer-institute/
Written by 586586BFF52FDED8981DAC13A2A3522284ABB83EE8D8CBD56AF4EE698712979C
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1658317203790331904
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1658496142039044097
- noteId - 1658496142039044097
- participantId -
- noteAuthorParticipantId - 586586BFF52FDED8981DAC13A2A3522284ABB83EE8D8CBD56AF4EE698712979C Participant Details
- createdAtMillis - 1684251268287
- tweetId - 1658317203790331904
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- The source in the follow-up tweet explains that these grants were to the National Cancer Institute, not personally to Dr. Bertagnolli. And the bulk of the huge dollar amount was an for a 6,000-patient cancer drug trial. https://www.dailysignal.com/2022/08/22/biden-picks-major-recipient-of-pfizer-research-dollars-to-oversee-cancer-institute/
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2023-05-16 15:34:28 UTC (1684251268287) |
1969-12-31 23:59:59 UTC (-1) |
2023-05-31 02:39:52 UTC (1685500792003) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
|||
| 2023-05-16 15:34:28 UTC (1684251268287) |
1969-12-31 23:59:59 UTC (-1) |
2023-05-17 02:21:24 UTC (1684290084375) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
| rated at | rated by | |
| 2023-05-16 14:47:02 -0500 | Rating Details | |
| 2023-05-16 14:18:13 -0500 | Rating Details | |
| 2023-05-16 14:17:25 -0500 | Rating Details | |
| 2023-05-16 14:12:16 -0500 | Rating Details | |
| 2023-05-16 13:59:13 -0500 | Rating Details | |
| 2023-05-16 13:50:45 -0500 | Rating Details | |
| 2023-05-16 13:25:47 -0500 | Rating Details | |
| 2023-05-16 13:15:33 -0500 | Rating Details | |
| 2023-05-16 13:00:37 -0500 | Rating Details | |
| 2023-05-16 12:16:52 -0500 | Rating Details | |
| 2023-05-16 12:05:35 -0500 | Rating Details | |
| 2023-05-16 11:35:52 -0500 | Rating Details | |
| 2023-05-16 11:32:57 -0500 | Rating Details | |
| 2023-05-16 11:32:40 -0500 | Rating Details | |
| 2023-05-16 11:24:44 -0500 | Rating Details | |
| 2023-05-16 11:18:14 -0500 | Rating Details | |
| 2023-05-16 11:12:22 -0500 | Rating Details | |
| 2023-05-16 10:56:34 -0500 | Rating Details | |
| 2023-05-16 10:45:19 -0500 | Rating Details | |
| 2023-05-16 10:43:09 -0500 | Rating Details | |
| 2023-05-16 10:39:10 -0500 | Rating Details | |
| 2023-05-16 10:36:38 -0500 | Rating Details | |
| 2023-05-16 10:35:50 -0500 | Rating Details | |
| 2023-05-17 03:11:26 -0500 | Rating Details | |
| 2023-05-16 23:29:13 -0500 | Rating Details | |
| 2023-05-16 23:18:45 -0500 | Rating Details | |
| 2023-05-16 21:25:33 -0500 | Rating Details | |
| 2023-05-16 21:08:55 -0500 | Rating Details | |
| 2023-05-17 22:29:02 -0500 | Rating Details | |
| 2023-05-19 09:13:03 -0500 | Rating Details | |
| 2023-05-16 13:59:13 -0500 | Rating Details | |
| 2023-05-16 11:18:14 -0500 | Rating Details | |
| 2023-05-16 10:56:34 -0500 | Rating Details | |
| 2023-05-16 13:15:33 -0500 | Rating Details | |
| 2023-05-17 22:29:02 -0500 | Rating Details | |
| 2023-05-16 21:08:55 -0500 | Rating Details | |
| 2023-05-16 11:35:52 -0500 | Rating Details | |
| 2023-05-16 10:43:09 -0500 | Rating Details | |
| 2023-05-16 12:05:35 -0500 | Rating Details | |
| 2023-05-16 11:24:44 -0500 | Rating Details | |
| 2023-05-16 14:12:16 -0500 | Rating Details | |
| 2023-05-16 13:50:45 -0500 | Rating Details | |
| 2023-05-16 23:18:45 -0500 | Rating Details | |
| 2023-05-16 14:47:02 -0500 | Rating Details | |
| 2023-05-16 13:00:37 -0500 | Rating Details | |
| 2023-05-16 11:32:57 -0500 | Rating Details | |
| 2023-05-16 14:18:13 -0500 | Rating Details | |
| 2023-05-16 10:36:38 -0500 | Rating Details | |
| 2023-05-16 11:12:22 -0500 | Rating Details | |
| 2023-05-17 03:11:26 -0500 | Rating Details | |
| 2023-05-19 09:13:03 -0500 | Rating Details | |
| 2023-05-16 10:39:10 -0500 | Rating Details | |
| 2023-05-16 21:25:33 -0500 | Rating Details | |
| 2023-05-16 12:16:52 -0500 | Rating Details | |
| 2023-05-16 10:45:19 -0500 | Rating Details | |
| 2023-05-16 10:35:50 -0500 | Rating Details | |
| 2023-05-16 11:32:40 -0500 | Rating Details | |
| 2023-05-16 14:17:25 -0500 | Rating Details | |
| 2023-05-16 13:25:47 -0500 | Rating Details | |
| 2023-05-16 23:29:13 -0500 | Rating Details |